 |
인쇄하기
취소
|
Boryung, Dongwha sign deal to sell antihypertensive drug
Boryung Pharm said Thursday it established a strategic partnership with Dongwha Pharm to sell the new combination form of an antihypertensive drug (fimasartan plus diuretic) in Korea and overseas.
Boryung completed the phase III clinical trial for such combination drug in May.
Under the deal, Dongwha will get the approval for sales and handle marketing in Korea over the next 20 years, und...
Boryung completed the phase III clinical trial for such combination drug in May.
Under the deal, Dongwha will get the approval for sales and handle marketing in Korea over the next 20 years, und...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.